Literature DB >> 19124601

Critical roles of inflammation and apoptosis in improved survival in a model of hyperoxia-induced acute lung injury in Pneumocystis murina-infected mice.

James M Beck1, Angela M Preston, Steven E Wilcoxen, Susan B Morris, Anne Sturrock, Robert Paine.   

Abstract

Pneumocystis infections increase host susceptibility to additional insults that would be tolerated in the absence of infection, such as hyperoxia. In an in vivo model using CD4-depleted mice, we previously demonstrated that Pneumocystis murina pneumonia causes significant mortality following an otherwise nonlethal hyperoxic insult. Infected mice demonstrated increased pulmonary inflammation and alveolar epithelial cell apoptosis compared to controls. To test the mechanisms underlying these observations, we examined expression of components of the Fas-Fas ligand pathway in P. murina-infected mice exposed to hyperoxia. Hyperoxia alone increased expression of Fas on the surface of type II alveolar epithelial cells; conversely, infection with P. murina led to increased lung expression of Fas ligand. We hypothesized that inhibition of inflammatory responses or direct inhibition of alveolar epithelial cell apoptosis would improve survival in P. murina-infected mice exposed to hyperoxia. Mice were depleted of CD4(+) T cells and infected with P. murina and then were exposed to >95% oxygen for 4 days, followed by return to normoxia. Experimental groups received vehicle, dexamethasone, or granulocyte-macrophage colony-stimulating factor (GM-CSF). Compared with the vehicle-treated group, treatment with dexamethasone reduced Fas ligand expression and significantly improved survival. Similarly, treatment with GM-CSF, an agent we have shown protects alveolar epithelial cells against apoptosis, decreased Fas ligand expression and also improved survival. Our results suggest that the dual stresses of P. murina infection and hyperoxia induce lung injury via activation of the Fas-Fas ligand pathway and that corticosteroids and GM-CSF reduce mortality in P. murina-infected mice exposed to hyperoxic stress by inhibition of inflammation and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19124601      PMCID: PMC2643641          DOI: 10.1128/IAI.00967-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial.

Authors:  S Gagnon; A M Boota; M A Fischl; H Baier; O W Kirksey; L La Voie
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

2.  A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; F R Sattler; J Chiu; A W Wu; D Gluckstein; C Kemper; A Bartok; J Niosi; I Abramson; J Coffman
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

3.  Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)

Authors:  J S Montaner; L M Lawson; N Levitt; A Belzberg; M T Schechter; J Ruedy
Journal:  Ann Intern Med       Date:  1990-07-01       Impact factor: 25.391

4.  Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism.

Authors:  Peter Y Hahn; Scott E Evans; Theodore J Kottom; Joseph E Standing; Richard E Pagano; Andrew H Limper
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

Review 5.  Role of cytokines in hyperoxia mediated inflammation in the developing lung.

Authors:  Porus Bustani; Sailesh Kotecha
Journal:  Front Biosci       Date:  2003-05-01

6.  Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice.

Authors:  R Paine; A M Preston; S Wilcoxen; H Jin; B B Siu; S B Morris; J A Reed; G Ross; J A Whitsett; J M Beck
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

7.  Pneumocystis pneumonia increases the susceptibility of mice to sublethal hyperoxia.

Authors:  James M Beck; Angela M Preston; Steven E Wilcoxen; Susan B Morris; Eric S White; Robert Paine
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

8.  Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury.

Authors:  Robert Paine; Steven E Wilcoxen; Susan B Morris; Claudio Sartori; Carlos E O Baleeiro; Michael A Matthay; Paul J Christensen
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

9.  Pneumocystis murina infection and cigarette smoke exposure interact to cause increased organism burden, development of airspace enlargement, and pulmonary inflammation in mice.

Authors:  Paul J Christensen; Angela M Preston; Tony Ling; Ming Du; W Bradley Fields; Jeffrey L Curtis; James M Beck
Journal:  Infect Immun       Date:  2008-05-19       Impact factor: 3.441

Review 10.  Alveolar cell death in hyperoxia-induced lung injury.

Authors:  Alessandra Pagano; Constance Barazzone-Argiroffo
Journal:  Ann N Y Acad Sci       Date:  2003-12       Impact factor: 5.691

View more
  11 in total

1.  TLR4-dependent GM-CSF protects against lung injury in Gram-negative bacterial pneumonia.

Authors:  Louis R Standiford; Theodore J Standiford; Michael J Newstead; Xianying Zeng; Megan N Ballinger; Melissa A Kovach; Ajaya K Reka; Urvashi Bhan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-09       Impact factor: 5.464

Review 2.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

3.  SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis.

Authors:  Renea P Jablonski; Seok-Jo Kim; Paul Cheresh; David B Williams; Luisa Morales-Nebreda; Yuan Cheng; Anjana Yeldandi; Sangeeta Bhorade; Annie Pardo; Moises Selman; Karen Ridge; David Gius; G R Scott Budinger; David W Kamp
Journal:  FASEB J       Date:  2017-03-03       Impact factor: 5.191

4.  Differential role of the Fas/Fas ligand apoptotic pathway in inflammation and lung fibrosis associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia and acute respiratory distress syndrome.

Authors:  Andrea D Lopez; Sreedevi Avasarala; Suman Grewal; Anuradha K Murali; Lucille London
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

5.  Pneumocystis jirovecii Rtt109, a novel drug target for Pneumocystis pneumonia in immunosuppressed humans.

Authors:  Jayme L Dahlin; Theodore Kottom; Junhong Han; Hui Zhou; Michael A Walters; Zhiguo Zhang; Andrew H Limper
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

6.  Key role of microRNA in the regulation of granulocyte macrophage colony-stimulating factor expression in murine alveolar epithelial cells during oxidative stress.

Authors:  Anne Sturrock; Mustafa Mir-Kasimov; Jessica Baker; Jesse Rowley; Robert Paine
Journal:  J Biol Chem       Date:  2013-12-26       Impact factor: 5.157

7.  GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.

Authors:  Qi-Xiang Rong; Fang Wang; Zhi-Xing Guo; Yi Hu; Sai-Nan An; Min Luo; Hong Zhang; Shao-Cong Wu; Hui-Qiang Huang; Li-Wu Fu
Journal:  Mol Cancer       Date:  2021-05-29       Impact factor: 27.401

8.  The bioactivity of soluble Fas ligand is modulated by key amino acids of its stalk region.

Authors:  Osamu Kajikawa; Raquel Herrero; Yu-Hua Chow; Chi F Hung; Gustavo Matute-Bello
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

9.  Targeting alveolar-specific succinate dehydrogenase A attenuates pulmonary inflammation during acute lung injury.

Authors:  Christine U Vohwinkel; Ethan J Coit; Nana Burns; Hanan Elajaili; Daniel Hernandez-Saavedra; Xiaoyi Yuan; Tobias Eckle; Eva Nozik; Rubin M Tuder; Holger K Eltzschig
Journal:  FASEB J       Date:  2021-04       Impact factor: 5.191

10.  Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-δ.

Authors:  Hanh Chi Do-Umehara; Cong Chen; Daniela Urich; Liang Zhou; Ju Qiu; Samuel Jang; Alia Zander; Margaret A Baker; Martin Eilers; Peter H S Sporn; Karen M Ridge; Jacob I Sznajder; G R Scott Budinger; Gökhan M Mutlu; Anning Lin; Jing Liu
Journal:  Nat Immunol       Date:  2013-03-24       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.